Promising cancer drug trial halted after just one patient
NCT ID NCT05987176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if giving Lutathera (a radioactive drug) after surgery to remove liver metastases from neuroendocrine tumors could help keep the cancer from coming back. It planned to compare Lutathera plus best supportive care against best supportive care alone in about 100 patients. However, the trial was terminated early after enrolling only 1 person, so no useful results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutathera (177Lu-DOTATATE)
- What this could lead to
- If it had worked, this could have pointed toward a way to delay or prevent cancer return after liver surgery for neuroendocrine tumors.
- What could go wrong
- The trial was terminated early with only 1 participant, so no conclusions can be drawn. Lutathera also carries risks like kidney and bone marrow damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can a black seed extract boost immunotherapy against a rare cancer?
- A new clue in the fight against colorectal cancer recurrence?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure